

# Risk and prognostic factors of breast cancer with liver metastases

**Lei ji**

Fudan University Shanghai Cancer Center

**Lei Cheng**

Fudan University Shanghai Cancer Center

**Xiuzhi Zhu**

Fudan University Shanghai Cancer Center

**Yu Gao**

Fudan University Shanghai Cancer Center

**Lei Fan**

Fudan University Shanghai Cancer Center

**zhonghua wang** (✉ [wangzhonghua2691@sina.com](mailto:wangzhonghua2691@sina.com))

Fudan University Shanghai Cancer Center <https://orcid.org/0000-0001-8792-3753>

---

## Research article

**Keywords:** Breast cancer, liver metastasis, risk factors, prognostic factors, HER2-targeted therapy

**Posted Date:** August 26th, 2020

**DOI:** <https://doi.org/10.21203/rs.3.rs-17121/v2>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

**Version of Record:** A version of this preprint was published on March 6th, 2021. See the published version at <https://doi.org/10.1186/s12885-021-07968-5>.

# Abstract

**Background:** Liver metastasis is a significant adverse predictor of overall survival (OS) among breast cancer patients. The purpose of this study was to determine the risk and prognostic factors of breast cancer with liver metastases (BCLM).

**Methods:** Data on 311,573 breast cancer patients from the Surveillance, Epidemiology, and End Results (SEER) database and 1728 BCLM patients from Fudan University Shanghai Cancer Center (FUSCC) were included. Logistic regression was used to identify risk factors for liver metastasis. Cox proportional hazards regression model was adopted to determine independent prognostic factors in BCLM patients.

**Results:** Young age, invasive ductal carcinoma, higher pathological grade, and subtype of triple-negative and human epidermal growth factor receptor 2 positive (HER2+) were risk factors for developing liver metastasis. The median OS after liver metastasis was 20.0 months in the SEER database and 27.3 months in the FUSCC dataset. Molecular subtypes also played a critical role in the survival of BCLM patients. We observed that hormone receptor-positive (HR+)/HER2+ patients had the longest median OS (38.0 for SEER vs. 34.0 months for FUSCC), whereas triple-negative breast cancer had the shortest OS (9.0 vs. 15.6 months) in both SEER and FUSCC. According to the results from the FUSCC, the subtype of HR+/HER2+ (hazard ratio (HR)=2.62; 95% confidence interval (CI)= 1.88-3.66;  $P<0.001$ ) and HR-/HER2+ (HR=3.43; 95% CI=2.28-5.15;  $P<0.001$ ) were associated with a significantly increased death risk in comparison with HR+/HER2- patients if these patients did not receive HER2-targeted therapy. For those who underwent HER2-targeted therapy, however, HR+/HER2+ subtype reduced death risk compared with HR+/HER2- subtype (HR=0.74; 95% CI=0.58-0.95;  $P<0.001$ ).

**Conclusions:** Breast cancer patients at a high risk for developing liver metastasis deserve more attention during the follow-up. BCLM patients with HR+/HER2+ subtype displayed the longest median survival than HR+/HER2- and triple-negative patients due to the introduction of HER2-targeted therapy and therefore it should be recommended for HER2+ BCLM patients.

## Background

Breast cancer is the most frequently diagnosed cancer and is the second leading cause of cancer-related death among women in developed countries[1]. More than 5% of cases are metastatic disease at the time of diagnosis, while almost 30% of patients newly diagnosed with localized or regional disease will recur [2, 3]. Early breast cancer patients has a 5-year survival rate of more than 90%, while it sharply decline to 26% for those with *de novo* metastatic breast cancer (MBC) [2]. Notably, the incidence of liver metastasis is only second to bone and lung metastasis, accounting for 71% of all patients in an autopsy study [4, 5]. Moreover, liver metastasis could result in treatment resistance and higher mortality. Median survival for breast cancer with liver metastases (BCLM) was only 3-15 months, with a 5-year survival rate of only 8.5 % [6, 7]. Because liver metastasis is an important factor influencing long-term survival of breast cancer patients, early identification may offer an opportunity for curative hepatic resection and prolonging the

survival time [8]. However, routine screening for distant metastasis among patients without clinical signs and symptoms related to relapse is not recommended according to breast cancer follow-up or surveillance guidelines due to lack of demonstrated clinical benefits [9]. Thus, BCLM patients who usually present asymptotically or with atypical symptoms tend to be ignored in the beginning stage of liver metastasis.

Several clinicopathological factors, especially molecular subtypes, can influence the occurrence and prognosis of liver metastasis. A study which included 3726 early breast cancer patients diagnosed from 1986 to 1992 showed that luminal/HER2 and HER2-enriched tumors were more susceptible to brain, liver, and lung metastases than luminal A tumors [10]. Dent et al. found that triple negative breast cancer had a higher risk of a visceral metastasis compared with other breast cancer subtypes [11]. Importantly, molecular subtypes are not only a risk factor for liver metastasis but also a predictor of clinical outcome of BCLM patients. A registry analysis of 500 BCLM patients found HR positive breast cancer reduced the risk of death by 33% compared with HR negative breast cancer [7]. A retrospective study of 145 BCLM patients also showed that estrogen receptor (ER) positive patients had a longer median than ER negative patients (7 vs 3.65 months) [12]. Additionally, multiple studies have shown that triple negative breast cancer has the worst prognosis among BCLM patients [13, 14]. There are some controversial or even contradicting results, however, regarding the prognostic value of molecular subtypes in BCLM patients. A previous study including 104 BCLM patients concluded that there was no impact of breast cancer subtypes on the survival after hepatic metastases [15]. A single center study of British population also presented similar results [16]. HER2 positive breast cancer is associated with a more aggressive phenotype and worse prognosis. In an earlier study, Kennecke et al. reported that MBC patients with luminal A subtype had longer survival than those with luminal/HER2 subtype (2.2 vs 1.3 years) owing to the lack of effective targeted therapy [10]. However, HER2 positive MBC patients with the addition of trastuzumab had better prognosis than those with HER2 negative disease historically considered to have a relatively favorable prognosis [17]. A recent population-based study on *de novo* BCLM patients also observed that patients with HR+/HER2+ subtype exhibited the longest median survival time of 31 months, substantially better than those with HR+/HER2- subtype (21 months) and other subtypes [14].

These above studies including a relatively small sample size are largely based on retrospective data and performed at a single academic center, yielding these different or even contradicting results. Our study aimed to explore risk factors for liver metastases (LM) to identify breast cancer patients at a high risk of liver metastasis at initial diagnosis. In addition, we hoped to detect independent prognostic factors in BCLM patients based on population-based data from the SEER database and large sample size data from the FUSCC dataset. As a result, we were able to evaluate the consistency and difference of these prognostic factors in two different populations and investigate the reasons behind.

## Methods

Within the SEER Research Data 1975–2016 dataset, breast cancer patients diagnosed from 2010 to 2016 were extracted[18]. Inclusion criteria were as follows: (a) age  $\geq 18$  years; (b) histologically confirmed

diseases; (c) known liver metastases status. The exclusion criteria were as follows: (a) carcinoma in situ; (b) multiple primary malignant tumors; (c) unknown follow-up or survival months of 0 month, including patients diagnosed via autopsy or a death certificate. Finally, there were 311573 breast cancer patients for further analysis, among whom there were 15884 patients with *de novo* MBC at initial diagnosis (Figure S1). Within the FUSCC dataset collected between 2007 and 2018, there were a total of 3453 female MBC patients. The diagnosis of liver metastases was based on the radiologic scan, the biopsy of metastatic lesions or the surgical resection specimens. Inclusion criteria were as follows: (a) age > 20 years; (b) histologically confirmed diseases; (c) developing liver metastases during the course of the disease; (d) detailed medical records. The exclusion criteria were as follows: (a) carcinoma in situ; (b) patients with bilateral breast cancer or other malignant diseases; (c) unknown follow-up. Ultimately, 1728 BCLM patients were eligible for subsequent analysis (Figure S2). Among 626 HER2 positive BCLM patients, 528 patients with subsequent HER2-targeted therapy information were enrolled to explore the effect of HER2-targeted therapy. Last follow-up was conducted on June 15, 2019, and the median follow-up time was 17.4 months (interquartile range [IQR], 8.5 to 31.0 months).

Incidence was defined as the number of BCLM patients divided by the total number of breast cancer patients or MBC patients in the SEER database. First liver metastases referred to liver metastases as the initial metastatic site, while subsequent liver metastases suggested that breast cancer cells gradually metastasized to the liver in the development of disease. Breast cancer subtypes were categorized as follows: HR-positive/HER2-negative (HR+/HER2-); HR+/HER2+; HR-/HER2+; HR-/HER2- (triple-negative) and unknown. Variables in this study included demographic characteristics and clinicopathological factors such as histology, pathological grade, number of extrahepatic metastatic sites, treatment information and subtype. OS was calculated from the date of diagnosis of liver metastases to the date of death from any cause, and patients alive at the date of last follow-up were censored.

Multivariate logistic regression analyses were performed to determine the risk factors associated with the presence of liver metastases at initial diagnosis. Odds ratios (ORs) with 95% CIs were also calculated. Univariate and multivariate Cox regression analyses were adopted to identify the prognostic factors associated with increased all-cause mortality. We also calculated HRs and 95% CIs in the Cox regression model. The consistency and difference of these prognostic factors in two different populations was evaluated on the basis of the data from the SEER database and the FUSCC dataset, and then we attempted to explore the possible causes behind. The Kaplan–Meier method and a log-rank test were used to estimate survival and evaluate differences between survival curves. Statistical analyses were performed using R (version 3.5.1), and a two-sided *P*-value less than 0.05 was considered statistically significant.

## Results

### Baseline characteristics and the incidence of liver metastases

A total of 311573 patients from SEER database diagnosed between 2010 and 2016 were included in the present study. Of these patients, there were 15884 MBC patients and 4067 BCLM patients at initial diagnosis (**Table 1**). In the FUSCC dataset, there were 1728 of 3048 metastatic breast cancer patients had liver metastases during the follow-up (**Table 2**). The consistent and inconsistent characteristics of two datasets were shown in **Table 1 and 2**. The baseline characteristics showed a higher proportion of patients with infiltrating duct carcinoma (73.1% vs 80.8%), extrahepatic metastases (73.9% vs 67.5%) and HR+/HER2- subtype (39.6% vs 44.3%) in the both SEER and FUSCC dataset. However, the differences between SEER and FUSCC were significant as well, such age, race, stage at initial diagnosis. The patients in the FUSCC dataset were younger and almost all of them were Asian patients, different from those in the SEER database. Most notably, the majority of FUSCC patients (88.3%) were recurrent breast cancer who underwent curative resection for primary tumors while all patients from the SEER database were diagnosed with *de novo* metastatic breast cancer.

As presented in **Table S1**, the 4067 BCLM patients accounted for 1.31% of the entire cohort and 25.6% of the MBC patients, including 1612 patients with HR+/HER2- subtype tumors (39.64%), 884 with HR+/HER2+ tumors (21.74%), 601 with HR-/HER2+ tumors (14.78%), 544 with triple-negative tumors (13.38%), and 426 with unknown tumors (10.47%). The proportion of patients with HR-/HER2+ tumors ranked highest (4.27% of the entire cohort and 44.13% of the metastatic subclass), while those with HR+/HER2- tumors ranked lowest proportion in both entire and metastatic patients (0.76% of the entire cohort and 19.34% of the metastatic subclass, **Table S1**). For patients from FUSCC, patients with first liver metastases attributed to 35.59% proportion of all MBC patients (**Table S2**).

### **Risk factors for liver metastasis**

Using breast cancer patients aged between 18-40 as reference, the increase of age was associated with significant trend towards decreased risk of liver metastasis, with OR of 0.59, 0.46, and 0.46 for those aged between 41-60, 61-80 and those older than 80-years age, respectively ( $P < 0.001$  for all, **Table 3**). The risk of liver metastasis was decreased in Hispanic (OR=0.82, 95% CI=0.74-0.91;  $P < 0.001$ ) and Asian or Pacific Islander patients (OR=0.81; 95% CI=0.72-0.92;  $P = 0.001$ ), but was increased for black patients (OR=1.54; 95% CI=1.41-1.67;  $P < 0.001$ ) in comparison with white patients. Married (OR=0.64; 95% CI=0.60-0.68;  $P < 0.001$ ) and insured status (OR=0.53; 95% CI=0.45-0.63;  $P < 0.001$ ) was associated with significantly decreased risk of liver metastasis when compared with the status of unmarried and uninsured, respectively. Compared with infiltrating duct carcinoma, lobular carcinoma (OR=0.68; 95% CI=0.59-0.77;  $P < 0.001$ ) and the mix of infiltrating duct and lobular carcinoma (OR=0.66; 95% CI=0.55-0.79;  $P < 0.001$ ) were both associated with decreased risk of liver metastasis. Tumors with higher pathological grade more inclined to metastasize to liver, in the comparison of grade II versus I (OR= 3.89; 95% CI=3.28-4.65;  $P < 0.001$ ) and grade III/IV versus I (OR=8.59; 95% CI=7.26-10.23;  $P < 0.001$ ). The analysis on molecular subtype indicated that HR+/HER2+ (OR=3.13; 95% CI=2.87-3.41;  $P < 0.001$ ), HR-/HER2+ (OR=4.75; 95% CI= 4.30-5.25;  $P < 0.001$ ), and triple-negative subtypes (OR=1.92; 95% CI=1.73-2.12;  $P < 0.001$ ) were all predictors for increased risk of liver metastasis in comparison with HR+/HER2- subtype, indicating the important role in disease progression played by HER2 status.

## Survival and prognostic factors

Median survival among BCLM patients, as stratified by subtype, is displayed in Table S1 and S2. The median survival among the entire cohort was 20.00 months in the SEER database (vs 27.30 months in the FUSCC dataset), with patients with the HR+/HER2+ subtype experiencing the longest median survival (38.00 vs 34.00 months) and patients with the triple-negative subtype experiencing the shortest median survival (9.00 vs 15.63 months) in the two cohorts. Additionally, breast cancer patients with first liver metastases showed distinctly longer survival times than those patients with subsequent liver metastases when the time was calculated from the diagnosis of liver metastasis (33.80 vs 17.47 months, **Figure 2A**). However, patients with liver metastases had a shorter survival time than breast cancer patients developing liver metastases during the subsequent disease course when the time was calculated from the diagnosis of MBC (42.57 vs 33.80 months, **Figure 2B**). The overall survival of all BCLM patients and the overall survival stratified by subtype or extent of extrahepatic metastatic disease are graphically displayed in **Figure 1**.

Multivariate Cox proportional hazards models were used to assess the prognostic factors of patients with BCLM in the SEER database (**Table 4**) and the FUSCC dataset was used for further exploration (**Table 5**). In the SEER database, older patients had worse survival, with a HR of 1.39, 1.84 and 3.62 for patients aged 41-60, 61-80, and >80 years in comparison with those aged 18-40 years ( $P<0.001$  for all). Moreover, black and Hispanic race were associated with increased death risk compared with white race, with a HR of 1.35 ( $P<0.001$ ) and 1.16 ( $P=0.028$ ), respectively). Results also showed a prolonged survival in presence of the status of married and insurance (HR=0.84 for married vs. unmarried, and 0.71 for insured vs. uninsured, with  $P<0.001$  for all). For the survival comparisons among clinical factors, we found that increased pathological grade, treatment without chemotherapy and surgery of primary site, increased number of extrahepatic metastatic sites and triple-negative pathological type were all associated with poor prognosis. Specifically, compared with grade I disease, the HR was 1.35 ( $P=0.013$ ) for grade II and 1.69 for grade III-IV ( $P<0.001$ ), respectively. Treatment without surgery of primary site and chemotherapy generated a HR of 1.52 and 1.63, respectively compared with those received the treatments ( $P<0.001$  for all). As expected, the HR increased from 1.42 to 3.43 as number of extrahepatic sites increased from 1 to 3, compared with no extrahepatic metastasis ( $P<0.001$  for all). In line of most previous studies, triple-negative subtype remained the deadliest type of cancer, with HR of 2.46 in comparison with HR+/HER2- cancers ( $P<0.001$ ). Interestingly, compared with HR+/HER2- subtype, we observed that HER2+ might decrease the death risk in the SEER database, with HR of 0.69 for HR+/HER2+ ( $P<0.001$ ) and 0.85 ( $P=0.014$ ) for HR-/HER2+ subtype, probably due to the introduction of HER2-targeted therapy.

Despite the substantial differences in baseline characteristics, the significant association of older age and greater number of extrahepatic metastasis sites with worse prognosis of the BCLM patients was also successfully observed in FUSCC datasets, similar to the former observation in the SEER database (**Table 5**). Additionally, histological type exerted no effect on the prognosis and patients with triple negative BCLM had the worst survival in both SEER and FUSCC dataset. Notably, specific results were obtained due to data availability in two different populations, such as race, marital and insurance status,

pathological grade and recurrent sequence. However, no significant difference was observed between survival of HER2+ patients with HR+/HER2- patients ( $P>0.05$ ) in FUSCC dataset different from the result of SEER database, probably owing to difference in clinical application of HE2-targeted therapies.

### HER2-targeted therapy

Owing to inconsistent results in the terms of the prognostic influence of molecular subtype in BCLM patients, we next explored whether HER2-targeted therapy led to these results. According to the results from the FUSCC, we found that in patients who did not receive HER-2 targeted therapy after liver metastases, HER2+ patients had an unfavorable prognosis compared with HR+/HER2- patients, with HR of 2.62 for HR+/HER2+ and 3.43 for HR-/HER2+ patients ( $P<0.001$  for all, **Table 6**). However, HR+/HER2+ patients had a better prognosis than HR+/HER2- patients in patients who underwent HER2-targeted therapy after liver metastasis, with HR of 0.74 ( $P<0.001$ ). Unfortunately, we only observed an insignificant trend towards decreased death risk induced by HER2-targeted therapy for HR-/HER2+ patients compared with HR+/HER2- patients, with a HR of 0.81 ( $P=0.110$ ). Overall survival among BCLM patients with or without HER2-targeted therapy stratified by subtype were visualized in **Figure 2**.

## Discussion

The risk factors for liver metastasis and prognostic factors of BCLM patients was described in this study. It was reported that the incidence of liver as the first metastatic site varied from 17.8%-35% [7, 19, 20]. We found that the incidence of first liver metastases was 25.6% in the SEER database and 35.59% in the FUSCC database, similar to these previous studies.

In addition to multiple molecular mechanisms underlying liver metastasis in breast cancer patients, a positive correlation between the occurrence of liver metastasis and multiple clinicopathological features, such as young age, invasive ductal carcinoma, higher pathological grade, and subtype of HER2+, was found in our study. The risk for liver metastasis surprisingly decreased with increasing age, which may result from a decrease in tumor-proliferative factors or deterioration of the immune system among patients of advanced age [21, 22]. Zengel et al found that invasive lobular carcinoma and mixed-type tumors had a higher incidence of bone metastasis than invasive ductal carcinoma, suggesting the potential role of histological type in the development of liver metastasis of breast cancer [23]. Infiltrating duct carcinoma was also found to be strongly associated with the occurrence of liver metastasis in our study. Purushotham et al demonstrated that the higher the histological grade of the breast cancer, the higher the risk of developing visceral metastasis because high histological grade also correlated positively with proliferation and metastasis capacity of tumor cells [22]. In addition, our present results also confirmed that HER2-positive or triple-negative subtype had significantly greater odds of developing liver metastases than HR+/HER2- subtype, consistent with previously published studies focused on the metastatic pattern of different breast cancer subtype [10, 19, 20, 22]. HER2 could upregulate the expression of the chemokine receptor CXCR4 and therefore promoted liver metastasis via the CXCL12/CXCR4 pathway, while elevated expression of the fibroblast growth factor homologous factor

(FGF13) could mediate the formation of liver metastases in the triple negative breast cancer, resulting in molecular subtype-based liver metastasis of breast cancer[24-26]. A recent study reported the first discovery of the functional role of the DNA of neutrophil extracellular traps (NETs) in promoting breast cancer liver metastasis, a mechanism distinct from previous studies on cytokines and chemokine receptors, integrin complexes, metabolic program and proliferation signaling [27, 28]. Early detection of liver metastases seemed to confer better outcomes of specific patients due to more effective treatments and better tolerance [29-34]. However, guidelines have reiterated that routine laboratory and imaging examination may not be applicable for patients with early breast cancer in the absence of signs or symptoms of metastatic disease because these examinations may not bring more survival benefits [35-37]. Our results can help to identify breast cancer patients at high risk for developing liver metastasis.

The median survival after liver metastasis was 20.00 months in the SEER database (vs 27.30 months in the FUSCC dataset) and varied significantly by molecular subtype. In both SEER database and FUSCC dataset, HR+/HER2+ patients had the longest survival (38.00 vs 34.00 months), whereas triple negative breast cancer had the worst prognosis (9.00 vs 15.63 months). Both HR+/HER2+ and HR-/HER2+BCLM patients had a more favorable outcome than HR+/HER2-BCLM patients in the SEER database, but there was no significant difference in the FUSCC dataset. We hypothesized that it may originate from disparities in the application of HER2-targeted therapy. According to the results from FUSCC, HER2 positive BCLM patients who did not receive HER2-targeted therapy after liver metastases had worse outcomes than HR+/HER2- patients, whereas significantly improved clinical outcomes were observed among those patients undergoing HER2-targeted therapy, in accordance with results from the SEER database. While there was still not a substantial survival advantage of HR+/HER2- BCLM patients receiving HER2-targeted therapy in the FUSCC dataset, our findings could indicate that HR+/HER2+ or even HR-/HER2+ BCLM patients had a favorable prognosis than HR+/HER2- BCLM patients owing to the introduction of HER2-targeted therapy. The gene that encodes HER2 is amplified and overexpressed in 15-20% of newly diagnosed breast cancer and results in a worse survival [38, 39]. Nevertheless, diverse HER2-directed drugs have significantly improved survival in breast cancer patients with HER2-positive subtype [40-45]. Even for HER2positive metastatic breast cancer, antiHER2 therapy also results in considerable and long-lasting improvement in quality of life and overall survival[46]. Furthermore, continuous anti-HER2 therapy is of utmost significance for the improvement of survival outcomes in metastatic breast cancer[42, 47, 48]. However, these treatments are expensive and require professional guidance from oncologists, limiting their availability and continuous use for patients without health insurance or in lower income countries, which may explain differences in outcome between these two populations [46]. These inconsistent results on the prognostic role of molecular subtype in BCLM patients may also be explained by differences in baseline characteristics of two groups.

Novel treatment options and different metastatic sites profoundly changed the prognostic value of molecular subtype in breast cancer patients. HR+/HER2- breast cancer were historically considered to have a relatively favorable prognosis, whereas HR+/HER2+ subtype seemed to have the best prognosis and HR+/HER2- and HR-/HER2+ subtype had similar survival among patients with *de novo* metastatic breast cancer in the HER2-targeted therapy era [49, 50]. Among breast cancer patients with *de novo* brain

or bone metastases, results were consistent with those in *de novo* metastatic breast cancer patients [51, 52], while HR-/HER2+ subtype had a worse prognosis than the HR+/HER2- subtype among breast cancer patients with *de novo* lung metastases [53]. Differently, HR-/HER2+ BCLM patients may have a better prognosis than the HR+/HER2- subtype in our study. There are many potential reasons for these discrepancies. HR+/HER2- patients with visceral metastases are often considered to insensitive to endocrine therapy than those without visceral metastases[54]. In the FALCON study, the median progression-free survival (PFS) in patients receiving fulvestrant 500mg as first-line treatment with and without visceral disease was 13.8 months and 22.3 months, respectively[55]. M. He et al found that heterogeneity existed among different visceral metastatic sites, and the median PFS was longer in patients with lung metastases than in those with liver metastases after fulvestrant therapy (9.6 and 3.7 months, respectively,  $P < 0.001$ )[54]. Kimbung et al also identified a 17-gene liver metastasis-specific signature, which was significantly and independently prognostic for poor relapse-free and overall survival in ER-positive tumors[56]. Fortunately, substantial progress has been made after major advances in our understanding of the biology of ER+/HER2- breast cancer in the past 20 years, such as the development of CDK4/6 inhibitors, mTOR inhibitors, PI3K $\alpha$  inhibitors and histone deacetylase inhibitors[57]. Subgroup analyses suggested that patients with visceral metastases also benefited from the addition of these targeted therapies to endocrine therapy[58-61]. On the basis of the above findings, endocrine therapy combined with these novel targeted therapies may be more appropriate for HR+/HER2- BCLM patients than endocrine therapy alone, but further research is required.

## Limitations

We acknowledge that there are some limitations in our study. First, it was retrospective study including two groups with different baseline characteristics, yielding relatively different results. Second, some detailed information that may have effects on survival was not available, including other metastatic sites, such as the pleura and contralateral breast, number and maximum diameter of liver metastases and performance status. Third, we did not evaluate whether different HER2-targeted therapies, endocrine therapies and surgery on the prognosis of BCLM patients to provide individualized treatment for these specific populations.

## Conclusions

Despite these limitations, our study had a larger sample size and the majority of patients were more recently diagnosed than previous studies on this subject. As a result, our findings may be more reliable and representative. Breast cancer patients with young age, invasive ductal carcinoma, higher pathological grade, and triple-negative and HER2+ subtypes have a high risk of developing liver metastases at initial diagnosis, and therefore deserve more attention during the follow-up. Furthermore, HR+/HER2+ or even HR-/HER2+ BCLM patients had a better prognosis than HR+/HER2- BCLM patients owing to the introduction of HER2-targeted therapy. HER2-targeted based therapy may be the cornerstone of treatment for HER2+ BCLM patients.

# Declarations

## Ethics approval and consent to participate

This study was approved by the Institutional Ethics Review Board of FUSCC. All patients signed written informed consent before this study.

## Consent for publication

Not Applicable.

## Availability of data and materials

Any additional data/files can be obtained from the corresponding author on reasonable request.

## Competing Interests

The authors have declared that no competing interests exist.

## Funding

No funding was received in this study.

## Author Contributions:

LJ and LC contributed equally. Study concept and design: LF and ZW. Data collection, statistical analysis, or interpretation of data: All authors. Drafting of the manuscript: LJ, LC, LF and ZW. Critical revision of the manuscript: LF and ZW. Supervision: LF and ZW. All authors have read and approved the manuscript.

## Acknowledgements

We acknowledge Zhangru yang and Jianjiao Ni for critically reviewing the manuscript.

# Abbreviations

OS: overall survival;

BCLM: breast cancer with liver metastases;

SEER: Surveillance, Epidemiology, and End Results;

FUSCC: Fudan University Shanghai Cancer Center;

HER2: human epidermal growth factor receptor 2;

HR: hormone receptor;

+: positive;

-, negative;

HR, hazard ratio;

CI: confidence interval;

MBC: metastatic breast cancer;

ER: estrogen receptor;

LM: liver metastasis;

IQR: interquartile range;

ORs: Odds ratios;

FGF: fibroblast growth factor homologous factor;

NETs: neutrophil extracellular traps;

PFS: progression-free survival;

## References

1. Siegel RL, Miller KD, Jemal A: **Cancer statistics, 2019**. *CA Cancer J Clin* 2019, **69**(1):7-34.
2. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL, Siegel RL: **Cancer treatment and survivorship statistics, 2019**. *CA Cancer J Clin* 2019.
3. Redig AJ, McAllister SS: **Breast cancer as a systemic disease: a view of metastasis**. *J Intern Med* 2013, **274**(2):113-126.
4. Berman AT, Thukral AD, Hwang WT, Solin LJ, Vapiwala N: **Incidence and patterns of distant metastases for patients with early-stage breast cancer after breast conservation treatment**. *Clin Breast Cancer* 2013, **13**(2):88-94.
5. Cummings MC, Simpson PT, Reid LE, Jayanthan J, Skerman J, Song S, McCart Reed AE, Kutasovic JR, Morey AL, Marquart L *et al*: **Metastatic progression of breast cancer: insights from 50 years of autopsies**. *J Pathol* 2014, **232**(1):23-31.
6. Adam R, Aloia T, Krissat J, Bralet MP, Paule B, Giacchetti S, Delvart V, Azoulay D, Bismuth H, Castaing D: **Is liver resection justified for patients with hepatic metastases from breast cancer?** *Ann Surg* 2006, **244**(6):897-907; discussion 907-898.
7. Pentheroudakis G, Fountzilias G, Bafaloukos D, Koutsoukou V, Pectasides D, Skarlos D, Samantas E, Kalofonos HP, Gogas H, Pavlidis N: **Metastatic breast cancer with liver metastases: a registry**

- analysis of clinicopathologic, management and outcome characteristics of 500 women. *Breast Cancer Res Treat* 2006, **97**(3):237-244.
8. Adam R, Aloia T, Krissat J, Bralet M-P, Paule B, Giacchetti S, Delvart V, Azoulay D, Bismuth H, Castaing D: **Is liver resection justified for patients with hepatic metastases from breast cancer?** *Annals of surgery* 2006, **244**(6):897-908.
  9. **National Comprehensive Cancer Network.(NCCN) Clinical Practice Guidelines in Oncology.Breast Cancer, Version 2. 2019** [[https://www.nccn.org/professionals/physician\\_gls/pdf/breast.pdf](https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf)]
  10. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K: **Metastatic behavior of breast cancer subtypes.** *J Clin Oncol* 2010, **28**(20):3271-3277.
  11. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA: **Pattern of metastatic spread in triple-negative breast cancer.** *Breast cancer research and treatment* 2009, **115**(2):423-428.
  12. Wyld L, Gutteridge E, Pinder SE, James JJ, Chan SY, Cheung KL, Robertson JFR, Evans AJ: **Prognostic factors for patients with hepatic metastases from breast cancer.** *British journal of cancer* 2003, **89**(2):284-290.
  13. Duan XF, Dong NN, Zhang T, Li Q: **The prognostic analysis of clinical breast cancer subtypes among patients with liver metastases from breast cancer.** *Int J Clin Oncol* 2013, **18**(1):26-32.
  14. Xie J, Xu Z: **A Population-Based Study on Liver Metastases in Women with Newly Diagnosed Breast Cancer.** *Cancer Epidemiol Biomarkers Prev* 2019, **28**(2):283-292.
  15. Ge Q-D, Lv N, Kong Y-N, Xie X-H, He N, Xie X-M, Wei W-D: **Clinical characteristics and survival analysis of breast cancer molecular subtypes with hepatic metastases.** *Asian Pacific journal of cancer prevention : APJCP* 2012, **13**(10):5081-5086.
  16. Abbas H, Erridge S, Sodergren MH, Papoulas M, Nawaz A, Menon K, Heaton ND, Prachalias AA, Srinivasan P: **Breast cancer liver metastases in a UK tertiary centre: Outcomes following referral to tumour board meeting.** *Int J Surg* 2017, **44**:152-159.
  17. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH: **Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.** *J Clin Oncol* 2010, **28**(1):92-98.
  18. **Surveillance, Epidemiology, and End Results Program ,Research Data (1975-2016), National Cancer Institute(NCI), Division of Cancer Control and Population Sciences(DCCPS), Surveillance Research Program(SRP), released April 2019, based on the November 2018 submission** [<https://seer.cancer.gov/>]
  19. Sihto H, Lundin J, Lundin M, Lehtimäki T, Ristimäki A, Holli K, Sailas L, Kataja V, Turpeenniemi-Hujanen T, Isola J: **Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.** *Breast Cancer Research* 2011, **13**(5):R87.
  20. Soni A, Ren Z, Hameed O, Chanda D, Morgan CJ, Siegal GP, Wei S: **Breast Cancer Subtypes Predispose the Site of Distant Metastases.** *American Journal of Clinical Pathology* 2015, **143**(4):471-478.

21. van de Water W, Markopoulos C, van de Velde CJH, Seynaeve C, Hasenburg A, Rea D, Putter H, Nortier JWR, de Craen AJM, Hille ETM *et al*: **Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer.** *JAMA* 2012, **307**(6):590-597.
22. Purushotham A, Shamil E, Cariati M, Agbaje O, Muhidin A, Gillett C, Mera A, Sivanadiyan K, Harries M, Sullivan R *et al*: **Age at diagnosis and distant metastasis in breast cancer—a surprising inverse relationship.** *Eur J Cancer* 2014, **50**(10):1697-1705.
23. Zengel B, Yararbas U, Duran A, Uslu A, Eliyatkin N, Demirkiran MA, Cengiz F, Simsek C, Postaci H, Vardar E *et al*: **Comparison of the clinicopathological features of invasive ductal, invasive lobular, and mixed (invasive ductal + invasive lobular) carcinoma of the breast.** *Breast Cancer* 2015, **22**(4):374-381.
24. Zlotnik A, Burkhardt AM, Homey B: **Homeostatic chemokine receptors and organ-specific metastasis.** *Nature reviews Immunology* 2011, **11**(9):597-606.
25. Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, Zhou X, Xia W, Hortobagyi GN, Yu D *et al*: **Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis.** *Cancer cell* 2004, **6**(5):459-469.
26. Johnstone CN, Pattison AD, Harrison PF, Powell DR, Lock P, Ernst M, Anderson RL, Beilharz TH: **FGF13 promotes metastasis of triple-negative breast cancer.** *International journal of cancer* 2020:10.1002/ijc.32874.
27. Yang L, Liu Q, Zhang X, Liu X, Zhou B, Chen J, Huang D, Li J, Li H, Chen F *et al*: **DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25.** *Nature* 2020, **583**(7814):133-138.
28. Chen W, Hoffmann AD, Liu H, Liu X: **Organotropism: new insights into molecular mechanisms of breast cancer metastasis.** *NPJ Precis Oncol* 2018, **2**(1):4.
29. Lindgaard SC, Brinch CM, Jensen BK, Nørgaard HH, Hermann KL, Theile S, Larsen FO, Jensen BV, Michelsen H, Nelausen KM *et al*: **Hepatic arterial therapy with oxaliplatin and systemic capecitabine for patients with liver metastases from breast cancer.** *The Breast* 2019, **43**:113-119.
30. He X, Zhang Q, Feng Y, Li Z, Pan Q, Zhao Y, Zhu W, Zhang N, Zhou J, Wang L *et al*: **Resection of liver metastases from breast cancer: a multicentre analysis.** *Clin Transl Oncol* 2019.
31. Ruiz A, Castro-Benitez C, Sebahg M, Giacchetti S, Castro-Santa E, Wicherts DA, van Hillegersberg R, Paule B, Castaing D, Morere JF *et al*: **Repeat Hepatectomy for Breast Cancer Liver Metastases.** *Ann Surg Oncol* 2015, **22 Suppl 3**:S1057-1066.
32. Sadot E, Lee SY, Sofocleous CT, Solomon SB, Gönen M, Peter Kingham T, Allen PJ, DeMatteo RP, Jarnagin WR, Hudis CA *et al*: **Hepatic Resection or Ablation for Isolated Breast Cancer Liver Metastasis.** *Annals of Surgery* 2016, **264**(1):147-154.
33. Swaminath A, Massey C, Brierley JD, Dinniwell R, Wong R, Kim JJ, Velec M, Brock KK, Dawson LA: **Accumulated Delivered Dose Response of Stereotactic Body Radiation Therapy for Liver Metastases.** *International Journal of Radiation Oncology\*Biophysics\*Physics* 2015, **93**(3):639-648.
34. Trovo M, Furlan C, Polesel J, Fiorica F, Arcangeli S, Giaj-Levra N, Alongi F, Del Conte A, Militello L, Muraro E *et al*: **Radical radiation therapy for oligometastatic breast cancer: Results of a prospective**

- phase II trial.** *Radiotherapy and Oncology* 2018, **126**(1):177-180.
35. Brothers JM, Kidwell KM, Brown RK, Henry NL: **Incidental radiologic findings at breast cancer diagnosis and likelihood of disease recurrence.** *Breast Cancer Res Treat* 2016, **155**(2):395-403.
36. Puglisi F, Follador A, Minisini AM, Cardellino GG, Russo S, Andretta C, Di Terlizzi S, Piga A: **Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications.** *Ann Oncol* 2005, **16**(2):263-266.
37. Ravaioli A, Pasini G, Polselli A, Papi M, Tassinari D, Arcangeli V, Milandri C, Amadori D, Bravi M, Rossi D: **Staging of breast cancer: new recommended standard procedure.** *Breast cancer research and treatment* 2002, **72**(1):53-60.
38. King CR, Kraus MH, Aaronson SA: **Amplification of a novel v-erbB-related gene in a human mammary carcinoma.** *Science* 1985, **229**(4717):974-976.
39. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: **Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.** *science* 1987, **235**(4785):177-182.
40. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M *et al*: **Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.** *N Engl J Med* 2001, **344**(11):783-792.
41. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A *et al*: **Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.** *N Engl J Med* 2012, **366**(2):109-119.
42. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B *et al*: **Lapatinib plus capecitabine for HER2-positive advanced breast cancer.** *N Engl J Med* 2006, **355**(26):2733-2743.
43. Awada A, Colomer R, Inoue K, Bondarenko I, Badwe RA, Demetriou G, Lee SC, Mehta AO, Kim SB, Bachelot T *et al*: **Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.** *JAMA Oncol* 2016, **2**(12):1557-1564.
44. Ma F, Ouyang Q, Li W, Jiang Z, Tong Z, Liu Y, Li H, Yu S, Feng J, Wang S *et al*: **Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.** *J Clin Oncol* 2019:Jco1900108.
45. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Dieras V, Guardino E *et al*: **Trastuzumab emtansine for HER2-positive advanced breast cancer.** *N Engl J Med* 2012, **367**(19):1783-1791.
46. Hayes DF: **HER2 and Breast Cancer - A Phenomenal Success Story.** *N Engl J Med* 2019.
47. Bartsch R, Wenzel C, Altorjai G, Pluschnig U, Rudas M, Mader RM, Gnant M, Zielinski CC, Steger GG: **Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.** *J Clin Oncol* 2007, **25**(25):3853-3858.

48. von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, Maartense E, Zielinski C, Kaufmann M, Bauer W *et al*: **Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study**. *J Clin Oncol* 2009, **27**(12):1999-2006.
49. Leone JP, Leone J, Zwenger AO, Vallejo CT, Leone BA: **Prognostic Significance of Tumor Subtypes in Women With Breast Cancer According to Stage: A Population-based Study**. *Am J Clin Oncol* 2019, **42**(7):588-595.
50. Gong Y, Liu YR, Ji P, Hu X, Shao ZM: **Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study**. *Sci Rep* 2017, **7**:45411.
51. Gong Y, Zhang J, Ji P, Ling H, Hu X, Shao ZM: **Incidence proportions and prognosis of breast cancer patients with bone metastases at initial diagnosis**. *Cancer Med* 2018, **7**(8):4156-4169.
52. Martin AM, Cagney DN, Catalano PJ, Warren LE, Bellon JR, Punglia RS, Claus EB, Lee EQ, Wen PY, Haas-Kogan DA *et al*: **Brain Metastases in Newly Diagnosed Breast Cancer**. *JAMA Oncology* 2017, **3**(8).
53. Xiao W, Zheng S, Liu P, Zou Y, Xie X, Yu P, Tang H, Xie X: **Risk factors and survival outcomes in patients with breast cancer and lung metastasis: a population-based study**. *Cancer Med* 2018, **7**(3):922-930.
54. He M, Li JJ, Zuo WJ, Ji L, Jiang YZ, Hu XC, Wang ZH, Shao ZM: **Metastatic breast cancer patients with lung or liver metastases should be distinguished before being treated with fulvestrant**. *Cancer Med* 2019.
55. Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, Shparyk Y, Cardona-Huerta S, Cheung K-L, Philco-Salas MJ *et al*: **Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial**. *The Lancet* 2016, **388**(10063):2997-3005.
56. Kimbung S, Johansson I, Danielsson A, Veerla S, Egyhazi Brage S, Frostvik Stolt M, Skoog L, Carlsson L, Einbeigi Z, Lidbrink E *et al*: **Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer**. *Clin Cancer Res* 2016, **22**(1):146-157.
57. Turner NC, Neven P, Loibl S, Andre F: **Advances in the treatment of advanced oestrogen-receptor-positive breast cancer**. *The Lancet* 2017, **389**(10087):2403-2414.
58. Turner NC, Finn RS, Martin M, Im SA, DeMichele A, Ettl J, Dieras V, Moulder S, Lipatov O, Colleoni M *et al*: **Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases**. *Ann Oncol* 2018, **29**(3):669-680.
59. Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F *et al*: **Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer**. *N Engl J Med* 2012, **366**(6):520-529.
60. Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B *et al*: **Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer**. *N Engl J*

*Med* 2019, **380**(20):1929-1940.

61. Jiang Z, Li W, Hu X, Zhang Q, Sun T, Cui S, Wang S, Ouyang Q, Yin Y, Geng C *et al*: **Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.** *The Lancet Oncology* 2019, **20**(6):806-815.

## Tables

Table 1. Baseline characteristics of breast cancer with liver metastases at diagnosis in the SEER database.

Variable	Patients, No. %	
	Total (n=311573)	With Liver Metastases (n = 4067)
Age, y		
18-40	21313 (6.8%)	494 (12.1%)
41-60	137299 (44.1%)	1882 (46.3%)
61-80	129497 (41.6%)	1414 (34.8%)
>80	23464 (7.5%)	277 (6.8%)
Race		
White	207400 (66.6%)	2565 (63.1%)
Black	35062 (11.3%)	737 (18.1%)
Hispanic	37499 (12.0%)	427 (10.5%)
Asian or Pacific Islander	27997 (9.0%)	305 (7.5%)
American Indian/Alaska Native	1757 (0.6%)	23 (0.6%)
Unknown	1858 (0.6%)	10 (0.2%)
Marital status		
Unmarried <sup>a</sup>	123349 (39.6%)	2011 (49.4%)
Married	171728 (55.1%)	1827 (44.9%)
Unknown	16496 (5.3%)	229 (5.6%)
Insurance status		
Uninsured <sup>b</sup>	5417 (1.7%)	163 (4.0%)
Insured	300400 (96.4%)	3821 (94.0%)
Unknown	5756 (1.8%)	83 (2.0%)
Histology		
Infiltrating duct carcinoma	234958 (75.4%)	2971 (73.1%)
Lobular carcinoma	27050 (8.7%)	246 (6.0%)
Infiltrating duct and lobular carcinoma	16392 (5.3%)	133 (3.3%)
Other types <sup>c</sup>	33173 (10.6%)	717 (17.6%)
Pathological Grade		
I	66365 (21.3%)	144 (3.5%)
II	129786 (41.6%)	1147 (28.2%)
III/IV	98850 (31.7%)	1939 (47.7%)
Unknown	16572 (5.3%)	837 (20.6%)
Surgery of primary site		
Yes	285989 (91.8%)	952 (23.4%)
No	22831 (7.3%)	3052 (75.0%)
Unknown	2753 (0.9%)	63 (1.5%)
Radiotherapy		
Yes	162703 (52.2%)	1082 (26.6%)
No/Unknown	148870 (47.8)	2985 (73.4%)
Chemotherapy		
Yes	130572 (42.0%)	2802 (68.9%)
No/Unknown	181001 (58.1%)	1265 (31.1%)
Extrahepatic metastatic sites to lung, brain and bone, No		
0	298407 (95.8%)	1060 (26.1%)
1	9408 (3.0%)	1696 (41.7%)
2	2747 (0.9%)	891 (21.9%)
All 3	343 (0.1%)	177 (4.4%)
Unknown	668 (0.2%)	243 (6.0%)
Subtype		
HR+/HER2-	211127 (67.8%)	1612 (39.6%)
HR+/HER2+	32962 (10.6%)	884 (21.7%)
HR-/HER2+	14089 (4.5%)	601 (14.8%)
Triple-negative	33352 (10.7%)	544 (13.4%)
Unknown	20043 (6.4%)	426 (10.5%)

Notes: <sup>a</sup> including divorced, separated, single (never married), and widowed; <sup>b</sup> including insured  Insured/No specifics Any Medicaid; <sup>c</sup> including other histology of invasive breast cancer except Infiltrating duct carcinoma, Lobular carcinoma and Infiltrating duct and lobular carcinoma; + denotes

positive; - denotes negative; \* denotes a statistically significant *P*-value; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; OR, odds ratio; CI confidence interval

Table 2. Baseline characteristics of breast cancer patients with liver metastases in the FUSCC dataset.

Variable	Patients, No. % Patients (n=1728)
Age at diagnosis, y	
21-40	288 (16.7%)
41-60	1143 (66.1%)
>60	297 (17.2%)
Histology	
Infiltrating duct carcinoma	1396 (80.8%)
Lobular carcinoma	31 (1.8%)
Other	301 (17.4%)
<i>De novo</i> metastatic diseases	
No	1526 (88.3%)
Yes	202 (11.7%)
Surgery of primary site	
No	219 (12.7%)
Yes	1509 (87.3%)
Prior Chemotherapy	
No	226 (13.1%)
Yes	1502 (86.9%)
Prior Radiotherapy	
No	848 (49.1%)
Yes	785 (45.4%)
Unknown	95 (5.5%)
Recurrent sequence	
First liver metastases	1087 (62.9%)
Subsequent liver metastases	641 (37.1%)
Extrahepatic metastatic sites to lung, brain, bone and lymph nodes, No	
0	561 (32.5%)
1	534 (30.9%)
2	382 (22.1%)
3	223 (12.9%)
All 4	28 (1.6%)
Subtype	
HR+/HER2-	767 (44.3%)
HR+/HER2+	305 (17.7%)
HR-/HER2+	321 (18.6%)
Triple-negative	270 (15.6%)
Unknown	65 (3.8%)

Notes: + denotes positive; - denotes negative; \*denotes a statistically significant *P*-value; HER2, human epidermal growth factor receptor 2; HR, hormone receptor;

Table 3. Multivariate Logistic Regression for the risk factors of liver metastases at initial diagnosis of breast Cancer in the SEER database.

Variable	Among Entire Cohort Multivariate OR (95% CI)	PValue
Age at diagnosis, y		
18-40	1[Reference]	
41-60	0.59 (0.54-0.66)	<0.001*
61-80	0.46 (0.41-0.51)	<0.001*
>80	0.46 (0.40-0.54)	<0.001*
Race		
White	1[Reference]	
Black	1.54 (1.41-1.67)	<0.001*
Hispanic	0.82 (0.74-0.91)	<0.001*
Asian or Pacific Islander	0.81 (0.72-0.92)	0.001*
American Indian/Alaska Native	0.93 (0.59-1.38)	0.725
Unknown	0.38 (0.19-0.68)	<0.001*
Marital status		
Unmarried <sup>a</sup>	1[Reference]	
Married	0.64 (0.60-0.68)	<0.001*
Unknown	0.83 (0.72-0.96)	0.013*
Insurance status		
Uninsured <sup>b</sup>	1[Reference]	
Insured	0.53 (0.45-0.63)	<0.001*
Unknown	0.48 (0.35-0.67)	<0.001*
Histology		
Infiltrating duct carcinoma	1[Reference]	
Lobular carcinoma	0.68 (0.59-0.77)	<0.001*
Infiltrating duct and lobular carcinoma	0.66 (0.55-0.79)	<0.001*
Other types <sup>C</sup>	1.25 (1.14-1.37)	<0.001*
Pathological Grade		
I	1[Reference]	
II	3.89 (3.28-4.65)	<0.001*
III/IV	8.59 (7.26-10.23)	<0.001*
Unknown	20.75 (17.32-25.02)	<0.001*
Extrahepatic metastatic sites to lung, brain and bone, No		
0	1[Reference]	
1	58.49 (53.84-63.57)	<0.001*
2	123.15 (110.89-136.76)	<0.001*
All 3	246.17 (195.34-310.33)	<0.001*
Unknown	299.10 (240.01-372.94)	<0.001*
Subtype		
HR+/HER2-	1[Reference]	
HR+/HER2+	3.13 (2.87-3.41)	<0.001*
HR-/HER2+	4.75 (4.30-5.25)	<0.001*
Triple-negative	1.92 (1.73-2.12)	<0.001*
Unknown	1.48 (1.31-1.68)	<0.001*

Notes: <sup>a</sup> including divorced, separated, single (never married), and widowed; <sup>b</sup> including insured □ Insured/No specifics Any Medicaid; <sup>C</sup> including other histology of invasive breast cancer except Infiltrating duct carcinoma, Lobular carcinoma and Infiltrating duct and lobular carcinoma; + denotes positive; - denotes negative; \* denotes a statistically significant P-value; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; OR, odds ratio; CI confidence interval

Table 4. Univariate and Multivariate Cox Regression for OS of breast cancer with liver metastases at diagnosis in the SEER database.

Variable	Overall Survival Univariable		Multivariable	
	Hazard Ratio (95% CI)	PValue	Hazard Ratio (95% CI)	PValue
Age, y				
18-40	1 [Reference]		1 [Reference]	
41-60	1.52 (1.32-1.76)	<0.001*	1.39 (1.20-1.61)	<0.001*
61-80	2.17 (1.88-2.51)	<0.001*	1.84 (1.58-2.15)	<0.001*
>80	4.44 (3.65-5.39)	<0.001*	3.62 (2.76-4.74)	<0.001*
Race <sup>a</sup>				
White	1 [Reference]		1 [Reference]	
Black	1.21 (1.09-1.33)	<0.001*	1.35 (1.22-1.50)	<0.001*
Hispanic	0.99 (0.87-1.13)	0.895	1.16 (1.02-1.32)	0.028*
Asian or Pacific Islander	0.86 (0.74-1.02)	0.078	0.90 (0.76-1.05)	0.182
American Indian or Alaska Native	0.96 (0.58-1.59)	0.869	1.01 (0.60-1.68)	0.984
Unknown	0.34 (0.09-1.37)	0.129	0.28 (0.07-1.15)	0.078
Marital status				
Unmarried <sup>a</sup>	1 [Reference]		1 [Reference]	
Married	0.75 (0.70-0.82)	<0.001*	0.84 (0.77-0.91)	<0.001*
Unknown	0.96 (0.81-1.14)	0.664	0.89 (0.75-1.06)	0.200
Insurance status				
Uninsured <sup>b</sup>	1 [Reference]		1 [Reference]	
Insured	0.75 (0.62-0.91)	0.003*	0.71 (0.59-0.86)	<0.001*
Unknown	0.94 (0.68-1.30)	0.717	0.83 (0.57-1.22)	0.348
Histology				
Infiltrating duct carcinoma	1 [Reference]		1 [Reference]	
Lobular carcinoma	1.14 (0.97-1.34)	0.112	0.87 (0.74-1.03)	0.101
Infiltrating duct and lobular carcinoma	0.94 (0.68-1.30)	0.717	0.89 (0.70-1.13)	0.323
Other types <sup>c</sup>	1.43 (1.30-1.58)	<0.001*	1.18 (1.05-1.33)	0.005*
Pathological Grade				
I	1 [Reference]		1 [Reference]	
II	1.08 (0.86-1.37)	0.515	1.35 (1.07-1.72)	0.013*
III/IV	1.30 (1.04-1.64)	0.022*	1.69 (1.34-2.14)	<0.001*
Unknown	1.59 (1.26-1.01)	<0.001*	1.59 (1.23-2.05)	<0.001*
Surgery of primary site				
Yes	1 [Reference]		1 [Reference]	
No	1.72 (1.56-1.89)	<0.001*	1.52 (1.38-1.68)	<0.001*
Unknown	0.93 (0.62-1.38)	<0.001*	0.96 (0.64-1.43)	<0.001*
Radiotherapy				
Yes	1 [Reference]		1 [Reference]	
No/Unknown	1.03 (0.94-1.12)	0.528	0.95 (0.87-1.04)	0.270
Chemotherapy				
Yes	1 [Reference]		1 [Reference]	
No/Unknown	2.03 (1.87-2.20)	<0.001*	1.63 (1.50-1.78)	<0.001*
Extrahepatic metastatic sites to lung, brain and bone, No				
0	1 [Reference]		1 [Reference]	
1	1.49 (1.34-1.65)	<0.001*	1.42 (1.28-1.58)	<0.001*
2	1.94 (1.73-2.18)	<0.001*	1.85 (1.65-2.09)	<0.001*
All 3	2.94 (2.44-3.56)	<0.001*	3.43 (2.77-4.26)	<0.001*
Unknown	1.92 (1.62-2.28)	<0.001*	1.62 (1.36-1.93)	<0.001*
Subtype				
HR+/HER2-	1 [Reference]		1 [Reference]	
HR+/HER2+	0.59 (0.53-0.66)	<0.001*	0.69 (0.61-0.77)	<0.001*
HR-/HER2+	0.72 (0.63-0.82)	<0.001*	0.85 (0.74-0.97)	0.014*
Triple-negative	2.10 (1.88-2.35)	<0.001*	2.46 (2.18-2.77)	<0.001*
Unknown	1.54 (1.36-1.74)	<0.001*	1.38 (1.20-1.58)	<0.001*

Notes: <sup>a</sup> including divorced, separated, single (never married), and widowed; <sup>b</sup> including insured  
Insured/No specifics Any Medicaid; <sup>c</sup> including other histology of invasive breast cancer except  
Infiltrating duct carcinoma, Lobular carcinoma and Infiltrating duct and lobular carcinoma;  
+ denotes positive; - denotes negative; \* denotes a statistically significant *P*-value; HER2, human  
epidermal growth factor receptor 2; HR, hormone receptor; OR, odds ratio; CI confidence interval

Table 5. Univariate and Multivariate Cox Regression for OS among patients of Breast Cancer with Liver Metastases in the FUSCC dataset.

Variable	Overall Survival				
	Univariate			Multivariate	
	Hazard Ratio	(95% CI)	PValue	Hazard Ratio (95% CI)	PValue
Age at diagnosis, y					
21-40	1	[Reference]		1	[Reference]
41-60	1.34	(1.11-1.62)	0.003*	1.38	(1.09-1.74) 0.006*
>60	1.39	(1.10-1.75)	0.005*	1.55	(0.86-2.80) 0.145
Histology					
Infiltrating duct carcinoma	1	[Reference]		1	[Reference]
Lobular carcinoma	0.90	(0.56-1.43)	0.648	0.68	(0.41-1.14) 0.146
Other	0.72	(0.60-0.87)	<0.001*	1.05	(0.85-1.29) 0.661
<i>De novo</i> metastatic diseases					
No	1	[Reference]		1	[Reference]
Yes	0.40	(0.31-0.52)	<0.001*	0.67	(0.29-1.52) 0.337
Surgery of primary site					
No surgery	1	[Reference]		1	[Reference]
Yes	2.33	(1.83-2.98)	<0.001*	1.02	(0.50-2.09) 0.947
Prior Chemotherapy					
No	1	[Reference]		1	[Reference]
Yes	2.56	(1.99-3.28)	<0.001*	1.51	(0.88-2.60) 0.135
Prior Radiotherapy					
No	1	[Reference]		1	[Reference]
Yes	1.33	(1.17-1.51)	<0.001*	1.20	(1.04-1.39) 0.014*
Unknown	0.77	(0.54-1.08)	0.122	0.67	(0.45-0.99) 0.046*
Recurrent sequence					
First liver metastases	1	[Reference]		1	[Reference]
Subsequent liver metastases	2.16	(1.90-2.46)	<0.001*	1.58	(1.33-1.87) <0.001*
Extrahepatic metastatic sites to lung, brain, bone and lymph nodes, No					

0	1[Reference]		1[Reference]	
1	1.54 (1.30-1.83)	<0.001*	1.16 (0.95-1.41)	0.15
2	2.16 (1.80-2.59)	<0.001*	1.56 (1.23-1.97)	<0.001*
3	2.57 (2.08-3.18)	<0.001*	2.05 (1.51-2.79)	<0.001*
All 4	5.49 (3.56-8.47)	<0.001*	4.59 (2.42-8.69)	<0.001*
Subtype				
HR+/HER2-	1[Reference]		1[Reference]	
HR+/HER2+	0.82 (0.68-0.98)	0.033*	1.02 (0.83-1.25)	0.851
HR-/HER2+	0.84 (0.70-1.01)	0.067	1.13 (0.92-1.40)	0.242
Triple-negative	1.83 (1.53-2.20)	<0.001*	2.17 (1.78-2.63)	<0.001*
Unknown	1.11 (0.79-1.57)	0.544	1.63 (1.10-2.43)	0.015*

Notes: + denotes positive; - denotes negative; \*denotes a statistically significant *P*-value; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; CI confidence interval


Table 6. Multivariate Cox Regression for OS among patients of Breast Cancer Liver Metastases with or without HER2-targeted therapy in the FUSCC dataset.

Variable	Overall Survival With HER2-targeted therapy		Overall Survival Without HER2-targeted therapy	
	HR (95% CI)	<i>P</i> Value	HR (95% CI)	<i>P</i> Value
Subtype				
HR+/HER2-	1[Reference]		1[Reference]	
HR+/HER2+	0.74 (0.58-0.95)	0.017*	2.62 (1.88-3.66)	<0.001*
HR-/HER2+	0.81 (0.63-1.05)	0.110	3.43 (2.29-5.15)	<0.001*
Triple-negative	2.17 (1.78-2.63)	<0.001*	2.17 (1.78-2.63)	<0.001*

Adjust for other variables


+ denotes positive; - denotes negative; \* denotes a statistically significant *P*-value; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; CI confidence interval

## Figures



**Figure 1**

Overall Survival Among Patients of Breast Cancer with Liver Metastases A. Overall survival (SEER) B. Survival stratified by the extent of extrahepatic metastatic disease (SEER) C. Survival stratified by subtype (SEER) D. Overall survival (FUSCC) E. Survival stratified by the extent of extrahepatic metastatic disease (FUSCC) F. Survival stratified by subtype (FUSCC)



**Figure 2**

A. Survival stratified by Recurrent sequence (Time from diagnosis of liver metastases) B. Survival stratified by Recurrent sequence (Time from metastasis) C. Overall Survival Among Patients of Breast Cancer Liver Metastases with targeted therapy stratified by subtype (FUSCC) D. Overall Survival Among Patients of Breast Cancer Liver Metastases without targeted therapy stratified by subtype (FUSCC)

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [FigureS2.pdf](#)

- [FigureS1.pdf](#)
- [TableS2.docx](#)
- [TableS1.docx](#)